CN1303278B - 制备水不溶性物质微粒的组合物和方法 - Google Patents

制备水不溶性物质微粒的组合物和方法 Download PDF

Info

Publication number
CN1303278B
CN1303278B CN998067113A CN99806711A CN1303278B CN 1303278 B CN1303278 B CN 1303278B CN 998067113 A CN998067113 A CN 998067113A CN 99806711 A CN99806711 A CN 99806711A CN 1303278 B CN1303278 B CN 1303278B
Authority
CN
China
Prior art keywords
surface modifier
particle
block copolymer
phospholipid
egg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN998067113A
Other languages
English (en)
Chinese (zh)
Other versions
CN1303278A (zh
Inventor
S·克汉
G·W·帕斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
RTP PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTP PHARMA Inc filed Critical RTP PHARMA Inc
Publication of CN1303278A publication Critical patent/CN1303278A/zh
Application granted granted Critical
Publication of CN1303278B publication Critical patent/CN1303278B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CN998067113A 1998-03-30 1999-03-29 制备水不溶性物质微粒的组合物和方法 Expired - Fee Related CN1303278B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7980998P 1998-03-30 1998-03-30
US60/079,809 1998-03-30
PCT/US1999/006746 WO1999049846A2 (en) 1998-03-30 1999-03-29 Compositions containing microparticles of water-insoluble substances and method for their preparation

Publications (2)

Publication Number Publication Date
CN1303278A CN1303278A (zh) 2001-07-11
CN1303278B true CN1303278B (zh) 2010-06-23

Family

ID=22152962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN998067113A Expired - Fee Related CN1303278B (zh) 1998-03-30 1999-03-29 制备水不溶性物质微粒的组合物和方法

Country Status (14)

Country Link
US (1) US6387409B1 (cg-RX-API-DMAC7.html)
EP (1) EP1067914B1 (cg-RX-API-DMAC7.html)
JP (2) JP4709378B2 (cg-RX-API-DMAC7.html)
KR (1) KR100628341B1 (cg-RX-API-DMAC7.html)
CN (1) CN1303278B (cg-RX-API-DMAC7.html)
AT (1) ATE318132T1 (cg-RX-API-DMAC7.html)
AU (1) AU761205B2 (cg-RX-API-DMAC7.html)
CA (1) CA2326456C (cg-RX-API-DMAC7.html)
DE (1) DE69929959T2 (cg-RX-API-DMAC7.html)
ES (1) ES2257041T3 (cg-RX-API-DMAC7.html)
IL (3) IL138765A0 (cg-RX-API-DMAC7.html)
SE (1) SE0003429L (cg-RX-API-DMAC7.html)
TW (1) TWI267383B (cg-RX-API-DMAC7.html)
WO (1) WO1999049846A2 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
WO1999049846A2 (en) * 1998-03-30 1999-10-07 Rtp Pharma Inc. Compositions containing microparticles of water-insoluble substances and method for their preparation
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US8415329B1 (en) 1998-05-29 2013-04-09 Jagotec Ag Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
KR20010075713A (ko) * 1998-11-20 2001-08-09 추후제출 불용성 마이크로입자의 안정된 현탁액의 제조방법
JP4809533B2 (ja) 1998-11-20 2011-11-09 オバン・エナジー・リミテッド 分散し得るリン脂質で安定化されたミクロ粒子
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
CN1243538C (zh) * 2002-11-21 2006-03-01 武汉利元亨药物技术有限公司 熊果酸豆磷脂纳米粒冻干粉针及制备方法
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US20040178135A1 (en) * 2003-03-13 2004-09-16 Beplate Douglas K. Filtering device incorporating nanoparticles
WO2004103348A2 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
NZ546379A (en) * 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
CA2573668A1 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
JPWO2006057429A1 (ja) * 2004-11-24 2008-06-05 ナノキャリア株式会社 ブロックコポリマーのモーフォロジーの変化方法
AU2006259594A1 (en) * 2005-06-14 2006-12-28 Baxter Healthcare S.A. Pharmaceutical formulations for minimizing drug-drug interactions
WO2007008697A2 (en) * 2005-07-08 2007-01-18 University Of Chicago Compositions and methods for refolding of denatured proteins
AU2006315177A1 (en) * 2005-11-15 2007-05-24 Baxter Healthcare S.A. Compositions of lipoxygenase inhibitors
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
EP2632437A4 (en) * 2010-10-29 2014-03-19 Univ Western Health Sciences Ternary mixture formulations
US20140000540A1 (en) * 2012-06-27 2014-01-02 Shell Oil Company Fuel and engine oil composition and its use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX9201782A (es) 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
ATE198148T1 (de) * 1995-02-06 2001-01-15 Elan Pharma Int Ltd Formulierungen von verbindungen als nanopartikel dispergiert in verdaubaren ölen oder fettsäuren
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
WO1997014407A1 (en) * 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
JP2000516244A (ja) * 1996-08-22 2000-12-05 リサーチ・トライアングル・ファーマシューティカルズ 水不溶性物質の微粒子を含む組成物およびその製造方法
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
WO1999049846A2 (en) * 1998-03-30 1999-10-07 Rtp Pharma Inc. Compositions containing microparticles of water-insoluble substances and method for their preparation
WO2013047199A1 (ja) * 2011-09-30 2013-04-04 Jx日鉱日石金属株式会社 スパッタリングターゲット及びその製造方法

Also Published As

Publication number Publication date
CA2326456C (en) 2008-12-23
KR20010042103A (ko) 2001-05-25
EP1067914A2 (en) 2001-01-17
JP2002509876A (ja) 2002-04-02
EP1067914B1 (en) 2006-02-22
TWI267383B (en) 2006-12-01
KR100628341B1 (ko) 2006-09-27
AU761205B2 (en) 2003-05-29
ATE318132T1 (de) 2006-03-15
JP5539839B2 (ja) 2014-07-02
CA2326456A1 (en) 1999-10-07
IL138765A0 (en) 2001-10-31
ES2257041T3 (es) 2006-07-16
SE0003429D0 (sv) 2000-09-26
JP2011037889A (ja) 2011-02-24
JP4709378B2 (ja) 2011-06-22
CN1303278A (zh) 2001-07-11
SE0003429L (sv) 2000-11-23
DE69929959D1 (de) 2006-04-27
IL138765A (en) 2007-09-20
US6387409B1 (en) 2002-05-14
WO1999049846A2 (en) 1999-10-07
DE69929959T2 (de) 2006-11-02
IL162023A0 (en) 2005-11-20
AU3118599A (en) 1999-10-18
WO1999049846A3 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
CN1303278B (zh) 制备水不溶性物质微粒的组合物和方法
US6337092B1 (en) Composition and method of preparing microparticles of water-insoluble substances
US6228399B1 (en) Composition and method of preparing microparticles of water-insoluble substances
US8206746B2 (en) Microparticles of water-insoluble substances
JP4091658B2 (ja) 無菌条件下にろ過可能な安定化されたナノ粒子
AU767154B2 (en) Dispersible phospholipid stabilized microparticles
US9700866B2 (en) Surfactant systems for delivery of organic compounds
AU743917B2 (en) Compositions comprising microparticles of water-insoluble substances
MXPA99001691A (es) Composiciones que comprenden microparticulas de sustancias insolubles en agua, y metodo para su preparacion

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: JAGOTEC AG

Free format text: FORMER OWNER: SKEYI PHARMA CANADA INC.

Effective date: 20101117

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: QUEBEC, CANADA TO: MUTTENZ, SWITZERLAND

TR01 Transfer of patent right

Effective date of registration: 20101117

Address after: Mu Tengci, Switzerland

Patentee after: Jagotec AG

Address before: Quebec

Patentee before: Skeyi Pharma Canada Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100623

Termination date: 20160329